Antisense Oligonucleotides Industry 2021 Global Analysis, Size, Trends, Share, Growth, Competitive Landscape, Key Players, Regional And Industry Forecast To 2027
SEATTLE, April 08, 2021, (PHARMIWEB) — Global Antisense Oligonucleotides Market
Antisense oligonucleotides are short, single-strand RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins. However, these molecules begin functioning prior to the formation of proteins at the level of messenger RNA in the cell. Antisense oligonucleotides are used in treatment of oncology, diabetes, asthma, hair loss, and as Central Nervous System (CNS) therapeutics and inflammation therapeutics. These molecules also find extensive application in genomics. Some examples of antisense nucleotides include fomivirsen (to treat cytomegalovirus retinitis), and mipomersen (to treat high cholesterol).
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1879
Global Antisense Oligonucleotides Market Overview
One of the major factors spurring the growth of the global antisense oligonucleotides market is increasing product by the key market players. For instance, in 2015, Exiqon A/S acquired by Qiagen launched new LNA Antisense Oligonucleotide GapmeRs. LNA Antisense Oligonucleotide GapmeRs is used for inactivation of RNA in functional analysis. Antisense LNA is an alternative to the existing siRNAs. LNA Antisense Oligonucleotide are designed using advanced bioinformatics algorithm, which is combined with LNA (locked nucleic acid).
Furthermore, mergers and acquisitions by key players, in order to enhance their product offerings, is expected to act as a major driver for global antisense oligonucleotides market growth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—a pharmaceutical company—merged with Wave Life Sciences Ltd., which is involved in nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave Life Sciences Ltd. to develop antisense oligonucleotides for central nervous system disorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD), Spinocerebellar ataxia type 3 (SCA3), and Huntington’s disease. Lou Gehrig’s disease is also called as Amyotrophic lateral sclerosis (ALS). This acquisition will also help Takeda in gaining market share.
Global Antisense Oligonucleotides Market – Regional Analysis
North America is foreseen as the most dominant region in the global antisense oligonucleotides market over the forecast period. The regional market growth is attributed to the increasing approvals of new antisense oligonucleotide drugs in the region. For instance, in 2018, the U.S. FDA approved Nusinersen, which is marketed as Spinraza from Biogen Inc., a multinational biotechnology company. Nusinersen is the first drug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover, a robust drug pipeline is expected to contribute significantly to market growth in the region. For instance, in 2017, Bio Path Holding’s—an oncology focused biotechnology company— drug BP 1001 (liposomal Grb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001 (liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenous leukemia.
The key market players in Europe are focusing on strategic mergers and acquisitions in order to enhance their product offerings. This is further expected to aid in the growth of the European antisense oligonucleotides market. For instance, in 2014, Astra Zeneca Plc.,—a multinational pharmaceutical and biopharmaceutical company—merged with Ionis Pharmaceuticals, a pharmaceutical company. Astra Zeneca Plc. has strategically merged with Ionis Pharmaceuticals to develop delivery methods for antisense oligonucleotides, which would help in targeting the desired tissue more effectively. The other objective of this merger was to develop Ligand Conjugation Antisense (LICA) Technology. Furthermore, robust pipeline of key players is also expected to aid in growth of the market to a certain extent. For instance, in 2016, Ionis Pharmaceuticals, a pharmaceutical company completed phase 2 clinical trial of its drug IONIS STAT 3Rx. IONIS STAT 3Rx is used in treatment of advanced cancers and lymphoma.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1879
Global Antisense Oligonucleotides Market – Key Competitors
The leading players involved in the global antisense oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.
By Therapeutic Application:
- Ocular diseases
- Amyotrophic Lateral Sclerosis (ALS)
- Spinal Muscular Atrophy
- Hemorrhagic fever viruses
- Cytomegalovirus retinitis
By Distribution Channel:
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire